Cullinan Oncology (NASDAQ:CGEM) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Cullinan Oncology and ImmunityBio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cullinan Oncology | 0 | 1 | 3 | 0 | 2.75 |
ImmunityBio | 0 | 0 | 1 | 0 | 3.00 |
Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 48.19%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than ImmunityBio.
Valuation and Earnings
This table compares Cullinan Oncology and ImmunityBio's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cullinan Oncology | N/A | N/A | N/A | N/A | N/A |
ImmunityBio | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Cullinan Oncology and ImmunityBio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cullinan Oncology | N/A | N/A | N/A |
ImmunityBio | N/A | N/A | N/A |
Summary
Cullinan Oncology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.